Literature DB >> 28920105

The impact of von Willebrand factor on factor VIII memory immune responses.

Juan Chen1, Jocelyn A Schroeder1,2,3, Xiaofeng Luo1, Qizhen Shi1,2,3,4.   

Abstract

Immune tolerance induction (ITI) with aggressive infusion of factor VIII (FVIII) is the current strategy used to eradicate FVIII inhibitors and restore normal FVIII pharmacokinetics in inhibitor patients. Whether the use of FVIII products containing von Willebrand factor (VWF) will affect the efficacy of ITI is still controversial. In this study, we explored the impact of VWF on FVIII memory immune responses in hemophilia A (HA) mice. A T-cell proliferation assay and cytokine profile analysis were used to study FVIII-primed CD4+ T cells. When CD4+ T cells from primed FVIIInull mice were restimulated with recombinant human FVIII (rhF8) plus recombinant human VWF (rhVWF) in vitro, the percentages of daughter CD4+ T cells were significantly decreased compared with the groups cultured with rhF8 only. Levels of interferon-γ and interleukin 10 were significantly lower in the rhF8 plus rhVWF groups than in the rhF8 groups. When memory B-cell pools from primed FVIIInull mice were cultured with rhF8 with or without rhVWF to induce differentiation of memory B cells into antibody-secreting cells (ASCs), the number of ASCs was significantly lower in the rhF8 plus VWF group than in the rhF8 group. When memory B-cell pools were transferred into NSGF8KO mice followed by rhF8 immunization with or without rhVWF, the titers of anti-F8 inhibitors and total immunoglobulin G were significantly higher in the rhF8 group than in the rhF8 plus rhVWF group, with an average difference of 2.23- and 2.04-fold. Together, our data demonstrate that VWF attenuates FVIII memory immune responses in HA mice.

Entities:  

Year:  2017        PMID: 28920105      PMCID: PMC5600162          DOI: 10.1182/bloodadvances.2017009209

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  46 in total

Review 1.  Management of bleeding disorders in adults.

Authors:  F Peyvandi; R Klamroth; M Carcao; A B Federici; G DI Minno; V Jiménez-Yuste; E C Rodriguez Merchán
Journal:  Haemophilia       Date:  2012-05       Impact factor: 4.287

Review 2.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

Review 3.  Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.

Authors:  Antonio Coppola; Matteo N D Di Minno; Elena Santagostino
Journal:  Br J Haematol       Date:  2010-06-22       Impact factor: 6.998

4.  VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

Authors:  Suryasarathi Dasgupta; Yohann Repessé; Jagadeesh Bayry; Ana-Maria Navarrete; Bharath Wootla; Sandrine Delignat; Theano Irinopoulou; Caroline Kamaté; Jean-Marie Saint-Remy; Marc Jacquemin; Peter J Lenting; Annie Borel-Derlon; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

5.  Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.

Authors:  Qizhen Shi; Scot A Fahs; Erin L Kuether; Brian C Cooley; Hartmut Weiler; Robert R Montgomery
Journal:  Blood       Date:  2010-07-06       Impact factor: 22.113

6.  The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.

Authors:  Q Shi; J A Schroeder; E L Kuether; R R Montgomery
Journal:  J Thromb Haemost       Date:  2015-06-11       Impact factor: 5.824

7.  Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.

Authors:  Qizhen Shi; Erin L Kuether; Yingyu Chen; Jocelyn A Schroeder; Scot A Fahs; Robert R Montgomery
Journal:  Blood       Date:  2013-11-22       Impact factor: 22.113

Review 8.  Epidemiology of inhibitors and current treatment strategies.

Authors:  Wolfhart Kreuz; Carmen Escuriola Ettingshausen; Günter Auerswald; Inmaculada Martinez Saguer; Sabine Becker; Markus Funk; Christine Heller; Dieter Klarmann; Thomas Klingebiel
Journal:  Haematologica       Date:  2003-06       Impact factor: 9.941

9.  A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

Authors:  Flora Peyvandi; Pier M Mannucci; Isabella Garagiola; Amal El-Beshlawy; Mohsen Elalfy; Vijay Ramanan; Peyman Eshghi; Suresh Hanagavadi; Ramabadran Varadarajan; Mehran Karimi; Mamta V Manglani; Cecil Ross; Guy Young; Tulika Seth; Shashikant Apte; Dinesh M Nayak; Elena Santagostino; Maria Elisa Mancuso; Adriana C Sandoval Gonzalez; Johnny N Mahlangu; Santiago Bonanad Boix; Monica Cerqueira; Nadia P Ewing; Christoph Male; Tarek Owaidah; Veronica Soto Arellano; Nathan L Kobrinsky; Suvankar Majumdar; Rosario Perez Garrido; Anupam Sachdeva; Mindy Simpson; Mathew Thomas; Ezio Zanon; Bulent Antmen; Kaan Kavakli; Marilyn J Manco-Johnson; Monica Martinez; Esperanza Marzouka; Maria G Mazzucconi; Daniela Neme; Angeles Palomo Bravo; Rogelio Paredes Aguilera; Alessandra Prezotti; Klaus Schmitt; Brian M Wicklund; Bulent Zulfikar; Frits R Rosendaal
Journal:  N Engl J Med       Date:  2016-05-26       Impact factor: 91.245

10.  Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.

Authors:  Mohammad Qadura; Braden Waters; Erin Burnett; Rouzbeh Chegeni; Scott Bradshaw; Christine Hough; Maha Othman; David Lillicrap
Journal:  Blood       Date:  2009-05-01       Impact factor: 22.113

View more
  5 in total

1.  Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.

Authors:  Weiqing Jing; Juan Chen; Yuanhua Cai; Yingyu Chen; Jocelyn A Schroeder; Bryon D Johnson; Weiguo Cui; Qizhen Shi
Journal:  Blood Adv       Date:  2019-10-22

Review 2.  Role of von Willebrand factor in the angiogenesis of lung adenocarcinoma.

Authors:  Xin Li; Zhong Lu
Journal:  Oncol Lett       Date:  2022-05-05       Impact factor: 3.111

3.  Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.

Authors:  Zhen-Ping Chen; Pei-Jing Li; Gang Li; Ling Tang; Ying-Zi Zhen; Xin-Yi Wu; Xiao-Ling Cheng; Koon Hung Luke; Victor S Blanchette; Man-Chiu Poon; Qiu-Lan Ding; Run-Hui Wu
Journal:  Chin Med J (Engl)       Date:  2018-08-05       Impact factor: 2.628

Review 4.  Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.

Authors:  Yuanhua Cai; Qizhen Shi
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

5.  Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.

Authors:  Zekun Li; Zhenping Chen; Guoqing Liu; Xiaoling Cheng; Wanru Yao; Kun Huang; Gang Li; Yingzi Zhen; Xinyi Wu; Siyu Cai; Man-Chiu Poon; Runhui Wu
Journal:  Res Pract Thromb Haemost       Date:  2021-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.